- freely available
Int. J. Mol. Sci. 2012, 13(10), 13542-13553; doi:10.3390/ijms131013542
Published: 19 October 2012
Abstract: We found two NADH-dependent reductases (QNR and bacC) in Microbacterium luteolum JCM 9174 (M. luteolum JCM 9174) that can reduce 3-quinuclidinone to optically pure (R)-(−)-3-quinuclidinol. Alcohol dehydrogenase from Leifsonia sp. (LSADH) was combined with these reductases to regenerate NAD+ to NADH in situ in the presence of 2-propanol as a hydrogen donor. The reductase and LSADH genes were efficiently expressed in E. coli cells. A number of constructed E. coli biocatalysts (intact or immobilized) were applied to the resting cell reaction and optimized. Under the optimized conditions, (R)-(−)-3-quinuclidinol was synthesized from 3-quinuclidinone (15% w/v, 939 mM) giving a conversion yield of 100% for immobilized QNR. The optical purity of the (R)-(−)-3-quinuclidinol produced by the enzymatic reactions was >99.9%. Thus, E. coli biocatalysis should be useful for the practical production of the pharmaceutically important intermediate, (R)-(−)-3-quinuclidinol.
The chemical processes for obtaining optically pure compounds include enantiomer separation from a racemic mixture, derivation from natural substances and asymmetric synthesis. Of these, asymmetric organic synthesis is the most efficient and useful method of producing chiral synthons. Chiral metal catalysts such as BINAP-Ru  and chiral Co (II) salen complex [2,3] have been successfully used as chemical catalysts for synthesizing chiral alcohols or chiral diols from various ketones or epoxides in a number of cases. However, trace metal contamination left in the products and the high cost of catalysts are unresolved difficulties affecting many reactions. To overcome the issues of conventional processes, biocatalytic transformation using enzymes or microorganisms has been applied to the asymmetric reduction of ketones. These biocatalytic processes are more environmentally sustainable and thus more attractive for pharmaceutical manufacturing . In recent years, the asymmetric reduction of ketones with biocatalysts has been reported for the production of chiral alcohols and applied to industry [5–9].
(R)-(−)-3-Quinuclidinol, which has a bicyclic structure with a bridgehead nitrogen, is a valuable intermediate for pharmaceuticals. It has been used as the chiral synthon for a cognition enhancer, a bronchodilator and a urinary incontinence agent . The optical resolution of (±)-3-quinuclidinol esters by the hydrolysis reaction of protease has been reported . Moreover, a number of enzymes have been reported as catalysts for the reduction of 3-quinuclidinone to (R)-(−)-3-quinuclidinol [12–14]. To accelerate the bioreduction process, it is necessary to regenerate NAD(P)+ to NAD(P)H in situ. There have been many reports on the reproduction of NAD(P)H via coupling reactions using formate/formate dehydrogenase (FDH)  and glucose/glucose dehydrogenase (GDH) . In the regeneration of NAD(P)H, 2-propanol is another suitable hydrogen donor because of its chemical properties and low cost [17,18]. Recently, our research group reported an excellent alcohol dehydrogenase from Leifsonia sp. strain S749 (LSADH) for the synthesis of chiral alcohols and concomitant regeneration of NADH with 2-propanol [19–21]. Biocatalytic reaction using whole cells is more stable than isolated enzyme reaction, and can reduce the cost of catalysts and cofactors [21,22].
In this study, we report a bioreduction system for synthesizing (R)-(−)-3-quinuclidinol using a recombinant E. coli cell biocatalyst possessing 3-quinuclidinone reductase (QNR or bacC) from M. luteolum JCM 9174 and LSADH (Figure 1). The bacC gene, which consists of 768 nucleotides corresponding to 255 amino acid residues and is a constituent of the bacilysin synthetic gene cluster, was obtained by PCR based on homology with known genes . The qnr gene consisted of 759 nucleotides corresponding to 252 amino acid residues . Both enzymes belong to the short-chain alcohol dehydrogenase/reductase (SDR) family. QNR showed 37% homology with the bacC isolated from M. luteolum. The resulting E. coli biocatalyst exhibited a high level of production of (R)-(−)-3-quinuclidinol and enantioselectivity (150 mg/mL, >99.9% e.e.).
2. Results and Discussion
2.1. Construction of Expression Vector of QNR and LSADH
pET28a (Merck KGaA, Darmstadt, Germany) and pRSFDuet-1 (Merck) vectors have the kanamycin resistance gene. Therefore, it was not suitable to select the colony having both plasmids. Thus, the qnr gene was subcloned into NdeI-HindIII sites of pETDuet-1, which has an ampicillin resistance gene, from pET28-QNR  to give pETDuet-QNR. The lsadh gene was amplified by PCR with the following primers and using pKELA  as a template: LSADHforNde (5′-GAGATCATATGGCTCAGTACGACGTC-3′) (the NdeI site is underlined) and LSADHrevSal (5′-TTTGTCGACTCACTGGGCGGTGTAG-3′) (the SalI site is underlined) under the following conditions: 94 °C for 2 min, followed by 98 °C for 10 s, 60 °C for 30 s and 68 °C for 1 min for a total of 30 cycles in accordance with the manufacturer’s protocol for KOD FX DNA polymerase (Toyobo, Osaka, Japan). The PCR fragments were digested with NdeI and SalI and inserted into NdeI and XhoI sites of pRSFDuet-1 (Merck) to obtain pRSFDuet-LSADH. For the co-expression of the qnr and lsadh, E. coli BL21 (DE3) was transformed with pETDuet-QNR and pRSFDuet-LSADH. Unfortunately, we could not construct pETDuet-QNR-LSADH.
2.2. Construction of Expression Vector of bacC and LSADH
The PCR fragment of lsadh mentioned above was digested with NdeI and SalI, and then cloned into the NdeI and XhoI sites of pETDuet-1 to obtain pETDuet-LSADH. Then, to add the T7 promoter region into the upstream of the lsadh gene, the fragment was amplified again by PCR with the pETDuet-LSADH as a template and the following primers: pETUpstream-69214-3 (5′-ATGCGTCCGGCGTAGA-3′) and LSADHrevSal. The amplicon was digested with HindIII and SalI, and cloned into HindIII and XhoI sites of the pET28-bacC  to generate pET28-bacC-LSADH, in which the bacC and lsadh genes were connected in this order and each gene was under the control of the T7 promoter (Figure 2).
2.3. Enzymatic Activity of the E. coli Biocatalyst
Table 1 shows the results of the enzymatic activity of each E. coli biocatalyst. The activities of E. coli BL21(DE3)/pET28-QNR, E. coli BL21(DE3)/pET28-bacC and E. coli BL21/pKELA, in which the gene was independently expressed, indicated higher 3-quinuclidinone-reducing/2-propanol oxidizing activity than E. coli BL21 (DE3)/pETDuet-QNR/pRSFDuet-LSADH and E. coli BL21 (DE3)/pET28-bacC-LSADH, in which the two genes were co-expressed. The results suggested that the combination of two E. coli biocatalysts, for example, E. coli BL21(DE3)/pET28-QNR and E. coli BL21/pKELA, should be suitable for the conversion of 3-quinuclidinone.
Moreover, in order to increase the durability of the biocatalyst, we immobilized the recombinant E. coli cells including E. coli BL21(DE3)/pET28-QNR, E. coli BL21(DE3)/pET28-bacC and E. coli BL21/pKELA by coating the cell surface with polyethyleneimine (PI) and glutaraldehyde (GA) . Unfortunately, the activity of immobilized biocatalyst was not determined because the enzyme could not be extracted from the immobilized cells.
2.4. Evaluation of E. coli Biocatalyst and Optimization of the Reaction
Based on the enzyme activity shown in Table 1, we applied various combinations of biocatalysts to (R)-(−)-3-quinuclidinol synthesis. Table 2 summarizes the production level of (R)-(−)-3-quinuclidinol and the molar conversion yield. In all cases, the absolute configuration of (R)-(−)-3-quinuclidinol produced was >99.9%. Conversions of almost 100% were attained except for the combination of E. coli/pET28-bacC and E. coli/pKELA (ratio: 1:4), when the final 10% (w/v, 626 mM) of 3-quinuclidinone was employed in the reaction mixture. Low production was due to the insufficient 3-quinuclidinone-reducing activity of this combination of biocatalysts. Neither QNR nor bacC catalyzes the reverse reaction, (R)-(−)-3-quinuclidinol oxidation to 3-quinuclidinon [23,24]; therefore, the unfavorable equilibrium between alcohol and ketone was negligible. However, it was noted that the conversion yield decreased when 15% (w/v, 939 mM) 3-quinuclidinone was employed in the reaction mixture, even if twice the amount of biocatalyst was added. During the course of the study, we observed that more than 5% of 3-quinuclidinone in the reaction mixture seemed to inhibit the reaction rate, suggesting that a high concentration of 3-quinuclidinone has an inhibitory effect on the enzyme catalysts. Thus, we adopted a method of consecutive additions of 3-quinuclidinone (5% w/v) and 2-propanol (5% v/v) to the reaction mixture at 8 h intervals. Under the optimized conditions, combinations of E. coli/pET28-QNR and E. coli/pKELA (4:1), E. coli/pET28-QNR and E. coli/pKELA (1:1) and E. coli/pETDuet-QNR/pRSFDuet-LSADH biocatalysts gave complete conversions of 10% 3-quinuclidinone to (R)-(−)-3-quinuclidinol.
We measured the activity and stability of purified QNR and bacC [23,24] at various concentrations to check the effects on the enzymes of 2-propanol and the acetone produced. Polar organic solvents such as 2-propanol and acetone are known to inhibit enzyme activity . QNR showed greater stability than bacC in 2-propanol-KPB (pH 7.0) or acetone-KPB (pH 7.0) medium (Figure 3). BacC was especially unstable in both 10% mediums. Moreover, the specific activity of bacC in 2-propanol-KPB (pH 7.0) or acetone-KPB (pH 7.0) medium decreased as the concentrations of 2-propanol and acetone increased, while QNR barely decreased (Figure 4). The decline in specific activity of bacC in these media was much greater than that of QNR. Thus, the data confirmed that QNR was superior to bacC for the production of (R)-(−)-3-quinuclidinol in 2-propanol-KPB (pH 7.0) medium. The results also suggested that it is important to keep the concentrations of 2-propanol and acetone lower than 10% during the reaction. Therefore, consecutive additions of 3-quinuclidinone (5% w/v) and 2-propanol (5% v/v) to the reaction mixture at 8 h intervals suppressed the inhibitory effect of the polar organic solvent. In addition, an open reaction system without sealing was adopted to promote the vaporization of acetone from the reaction mixture. Itoh et al. reported that aeration is another effective method in asymmetric bioreduction processes using LSADH with 2-propanol to reduce the concentration of acetone .
However, it was impossible to accumulate more than 10% of (R)-(−)-3-quinuclidinol product in the reaction mixture using intact E. coli cells biocatalysts even after consecutive additions of the substrate and 2-propanol (Table 2).
2.5. Evaluation of Immobilized E. coli Biocatalyst and the Conversion Time Course
Immobilization of recombinant E. coli cells often increases the operational stability of biocatalysts in the synthetic reaction. Itoh et al. reported a simple immobilization method for recombinant E. coli biocatalyst (pKELA, LSADH) using PI and GA , and revealed its superior operational stability for the bioreduction of 4-hydroxy-2-butanone to (R)-1,3-butanediol in 10% 2-propanol-KPB (pH 7.0) medium . We applied this method for the immobilization of E. coli/pET28-QNR, E. coli/pET28-bacC and E. coli/pKELA. Complete conversion of 15% (w/v) (150 mg, 939 mM) 3-quinuclidinone to (R)-(−)-3-quinuclidinol was attained by a combination of immobilized E. coli/pET28-QNR and E. coli/pKELA, although the reaction time was extended (Figure 5 and Table 2). Low production of immobilized E. coli/pET28-bacC and E. coli/pKELA was probably due to the loss of bacC activity during the immobilization procedure. We speculated that the PI and GA polymer matrix constructed on the E. coli cell surface has cationic properties due to unreacted amino and imino groups of PI and hinders the access of cationic 3-quinuclidinone to the enzymes in the cells, making it possible to overcome the inhibitory effect of a high concentration of substrate. However, the lower accessibility of substrate to immobilized cells compared with intact cells prolonged the reaction time.
The production level of (R)-(−)-3-quinuclidinol in this study was the highest ever reported, indicating that E. coli biocatalysis would provide a practical method of producing important chiral compounds.
3. Experimental Section
3-Quinuclidinone hydrochloride was obtained from Sigma-Aldrich Chemical Co. (WI, USA). 3-Quinuclidinol and glutaraldehyde were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), and (R )-(−)-3-quinuclidinol from Kanto Chemical Co. (Tokyo, Japan). Polyethylenimine P-70 solution (30% (v/v) solution) was purchased from Wako Pure Chemical Industries (Osaka, Japan). All other chemicals used in this study were of analytical grade and commercially available.
3.2.1. Preparation of E. coli Biocatalysts Overproducing Recombinant Enzymes
E. coli BL21 (DE3)/pET28-QNR or E. coli BL21 (DE3)/pET28-bacC [23,24] were each grown in Luria-Bertani (LB) medium consisting of 1.0% (w/v) tryptone, 0.5% yeast extract and 0.5% NaCl (pH 7.0). Pre-cultivation was carried out in the medium (4 mL) containing 0.05 mg mL−1 kanamycin sulfate in a test tube for 12 h at 37 °C with shaking (180 rpm). One milliliter of the culture medium was added to fresh medium (100 mL) containing antifoam PE-H (final concentration of 0.1%), 0.05 mg mL−1 kanamycin sulfate and 0.4 mM isopropyl-β-d-1-thiogalactopyranoside (IPTG) in a shaking flask at 120 rpm and cultured at 37 °C for 24 h. After centrifugation (10,000g, 5 min), the precipitated cells from 100 mL of culture were washed once with 100 mM potassium phosphate buffer (KPB) (pH 7.0) and used as a biocatalyst. E. coli BL21/pKELA was cultured according to our previous paper . Cultivation of E. coli BL21(DE3)/pET28-bacC-LSADH was performed in the same manner as E. coli BL21(DE3)/pET28-QNR and E. coli BL21(DE3)/pET28-bacC. E. coli BL21(DE3)/pETDuet-QNR/pRSFDuet-LSADH were cultured with 0.05 mg mL−1 kanamycin sulfate, 0.1 mg mL−1 ampicillin and 0.4 mM IPTG. Cultured cells (1 mL) were disrupted by a sonication device (Ultrasonic Disruptor, Tomy Seiko, Tokyo, Japan), repeated three times at 40 W for 10 s with 10 s intervals for cooling. After centrifugation (10,000g, 20 min), the enzymatic activity in the supernatant was assayed as described below.
3.2.2. Immobilization Procedure of E. coli Cells
E. coli BL21 (DE3)/pET28-QNR, pET28-bacC and E. coli BL21/pKELA cells were immobilized after cultivation by the method described by Itoh et al.  with 3% (w/v) polyethyleneimine (PI) and 0.5% (w/v) glutaraldehyde (GA). These immobilized biocatalysts were also used for the reduction of 3-quinuclidinone.
3.2.3. Enzyme Assay
A spectrophotometric assay of 3-quinuclidinone reductase activity was performed by measuring the decrease in absorbance of NADH at 340 nm (ɛ = 6.22 mM−1 cm−1). The assay was performed in a reaction mixture consisting of 10 μmol of substrate, 0.3 μmol of NADH, 50 μmol of KPB (pH 7.0) and 10 μL of enzyme solution in a total volume of 1.0 mL. LSADH activity with 2-propanol (50 mM) was measured in the oxidative reaction. The reaction mixture consisted of 1 μmol NAD+, 50 μmol 2-propanol, 100 μmol KPB (pH 7.0) and 10 μL enzyme solution in a total volume of 1.0 mL. One enzyme unit was defined as the amount of enzyme that converted 1 μmol of NADH or NAD+ per min at 25 °C.
3.2.4. Effect of Organic Solvent for Enzymes
The stability of the purified enzymes (500 μg) [23,24] was measured after incubation in 2-propanol/acetone and 100 mM KPB (pH 7.0) medium at various concentrations in a total volume of 1 mL for 2, 4 and 6 h at 25 °C.
3.2.5. Biocatalytic Reaction to Reduce 3-Quinuclidinone to (R)-(−)-3-Quinuclidinol with a Coenzyme Regenerating System
The 3-quinuclidinone conversion reaction was carried out with the coenzyme regeneration system by LSADH. The reaction mixture consisted of 200 mM KPB (pH 7.0), 5% (w/v) 3-quinuclidinone, 1 mM NAD+, various E. coli biocatalysts and 5% (v/v) 2-propanol in a total volume of 1 mL. The reaction proceeded in an unsealed 5 mL vial to accelerate vaporization of the acetone produced at 25 °C with shaking (2500 rpm, Taitec, Saitama, Japan) for 24 h. Both 3-quinuclidinone and 2-propanol were added to the reaction mixture at 8 h intervals resulting in 10% or 15% 3-quinuclidinone/2-propanol in the reaction mixture. The E. coli biocatalysts used in Table 2 were as follows: (a) E. coli BL21 (DE3)/pET28-QNR and E. coli BL21/pKELA (total 5 mL or 10 mL culture broth), (b) E. coli BL21(DE3) pET28-bacC and E. coli BL21/pKELA (total 5 mL or 10 mL culture broth), (c) E. coli BL21 (DE3)/pETDuet-QNR/pRSFDuet-LSADH (total 5 mL culture broth), (d) E. coli BL21 (DE3)/pET28-bacC-LSADH) (total 5 mL culture broth), (e) immobilized E. coli BL21 (DE3)/pET28-QNR and E. coli BL21/pKELA (each prepared from 5 mL culture broth), and (f) immobilized E. coli BL21(DE3)/pET28-bacC and E. coli BL21/pKELA (each prepared from 5 mL culture broth). After the reaction, 1 mL of the reaction mixture was centrifuged (18,000g, 5 min) and mixed with 6 N NaOH (0.2 mL), and the product was extracted twice with 1-butanol (0.5 mL), which contained 5 mM 1-octanol as an internal standard. The 1-butanol layer was thoroughly dried with anhydrous Na2SO4 and analyzed by gas chromatography (GC) after centrifugation as described below.
3.2.6. Product Analysis by GC
The enantiomer of 3-quinuclidinol was analyzed by a GC system (HP 6890, Hewlett Packard, CA, USA) equipped with a chiral capillary column (CP-cyclodextrin-β-236-N19, 0.25 mm × 25 m, Varian, CA, USA) with a flame ionization detector. The GC conditions were as follows: the column temperature program ramped from 70 °C to 180 °C at 10 °C min−1, the injection and detection temperatures were 250 °C, and the He flow rate was 3.3 mL min−1 with a linear velocity of 50 cm s−1 and a split ratio of 50. The retention times were 8.17 min for the 1-octanol internal standard, 10.94 min for 3-quinuclidinon, 12.69 min for (S )-(+)-3-quinuclidinol and 12.77 min for (R)-(−)-3-quinuclidinol.
We successfully constructed a number of E. coli biocatalysts, in which the QNR/bacC and LSADH genes were independently or dependently expressed, to produce optically pure (R)-(−)-3-quinuclidinol. By optimizing the reaction conditions including the combination of E. coli biocatalysts, a production level of approximately 100 mg/mL was attained with the intact E. coli biocatalyst process. Moreover, the combination of immobilized E. coli/pET28-QNR and E. coli/pKELA biocatalysts improved the production level to 150 mg/mL (939 mM) with 100% conversion.
- Noyori, R.; Ohkuma, T. Asymmetric catalysis by architectural and functional molecular engineering: Practical chemo- and stereoselective hydrogenation of ketones. Angew. Chem 2001, 40, 40–73.
- Tokunaga, M.; Larrow, J.F.; Kakiuchi, F.; Jacobsen, E.N. Asymmetric catalysis with water: Efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis. Science 1997, 277, 936–938.
- Jacobsen, E.N.; Kakiuchi, F.; Konsler, R.G.; Larrow, J.F.; Tokunaga, M. Enantioselective catalytic ring opening of epoxides with carboxylic acids. Tetrahedron Lett 1997, 38, 773–776.
- Breuer, M.; Ditrich, K.; Habicher, T.; Hauer, B.; Kesseler, M.; Stürmer, R.; Zelinski, T. Industrial methods for the production of optically active intermediates. Angew. Chem 2004, 43, 788–824.
- Shimizu, S.; Kataoka, M.; Kita, K. Chiral alcohol synthesis with microbial carbonyl reductases in a water-organic solvent two-phase system. Ann. N. Y. Acad. Sci 1998, 864, 87–95.
- Matsuyama, A.; Yamamoto, H.; Kobayashi, Y. Practical application of recombinant whole-cell biocatalysts for the manufacturing of pharmaceutical such as chiral alcohols. Org. Process Res. Dev 2002, 6, 558–561.
- Nakamura, K.; Yamanaka, R.; Matsuda, T.; Harada, T. Recent development in asymmetric reduction of ketones with biocatalysts. Tetrahedron Asymmetry 2003, 14, 2659–2681.
- Kataoka, M.; Kita, K.; Wada, M.; Yasohara, Y.; Hasegawa, J.; Shimizu, S. Novel bioreduction system for the production of chiral alcohols. Appl. Microbiol. Biotechnol 2003, 62, 437–445.
- Goldberg, K.; Schroer, K.; Lutz, S.; Liese, A. Biocatalytic ketone reduction-a powerful tool for the production of chiral alcohols-part I: Processes with isolated enzymes. Appl. Microbiol. Biotechnol 2007, 76, 237–248.
- Prat, M.; Buil, M.A.; Fernandez, M.D.; Castro, J.; Monleon, J.M.; Tort, L.; Casals, G.; Ferrer, M.; Huerta, J.M.; Espinosa, S.; et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists. Bioorg. Med. Chem. Lett 2011, 21, 3457–3461.
- Nomoto, F.; Hirayama, Y.; Ikunaka, M.; Inoue, T.; Otsuka, K. A practical chemoenzymatic process to access (R)-quinuclidin-3-ol on scale. Tetrahedron Asymmetry 2003, 14, 1871–1877.
- Hashimoto, T.; Nakajima, K.; Ongena, G.; Yamada, Y. Two tropinone reductases with distinct stereospecificities from cultured roots of Hyoscyamus niger. Plant. Physiol 1992, 100, 836–845.
- Uzura, A.; Nomoto, F.; Sakoda, A.; Nishimoto, Y.; Kataoka, M.; Shimizu, S. Stereoselective synthesis of (R)-3-quinuclidinol through asymmetric reduction of 3-quinuclidinone with 3-quinuclidinone reductase of Rhodotorula rubra. Appl. Microbiol. Biotechnol 2009, 83, 617–626.
- Yamamoto, H.; Ueda, M.; Pan, R.; Hamatani, T. Methods for producing optically active alcohols. U.S. Patent 2003/0143700, 2003.
- Yamamoto, H.; Mitsuhashi, K.; Kimoto, N.; Kobayashi, Y.; Esaki, N. Robust NADH-regenerator: improved alpha-haloketone-resistant formate dehydrogenase. Appl. Microbiol. Biotechnol 2005, 67, 33–39.
- Kataoka, M.; Yamamoto, K.; Kawabata, H.; Wada, K.; Kita, H.; Yanase, H.; Shimizu, S. Stereoselective reduction of ethyl 4-chloro-3-oxobutanoate by Eschericha coli transformant cells coexpressiong the aldehyde reductase and glucose dehydrogenase genes. Appl. Microbiol. Biotechnol 1999, 51, 486–490.
- Bradshaw, C.W.; Fu, H.; Shen, G.J.; Wong, C.H. A Pseudomonas sp. alcohol dehydrogenase with broad substrate specificity and unusual stereospecificity for organic synthesis. J. Org. Chem 1992, 57, 1526–1532.
- Stampfer, W.; Kosjek, B.; Faber, K.; Kroutil, W. Biocatalytic asymmetric hydrogen transfer employing Rhodococcus ruber DSM 44541. J. Org. Chem 2003, 68, 402–406.
- Inoue, K.; Makino, Y.; Itoh, N. Production of (R)-chiral alcohols by a hydrogen-transfer bioreduction with NADH-dependent Leifsonia alcohol dehydrogenase (LSADH). Tetrahedron Asymmetry 2005, 16, 2539–2549.
- Inoue, K.; Makino, Y.; Dairi, T.; Itoh, N. Gene cloning and expression of Leifsonia alcohol dehydrogenase (LSADH) involved in asymmetric hydrogen-transfer bioreduction to produce (R)-form chiral alcohols. Biosci. Biotechnol. Biochem 2006, 70, 418–426.
- Itoh, N.; Isotani, K.; Nakamura, M.; Inoue, K.; Isogai, Y.; Makino, Y. Efficient synthesis of optically pure alcohols by asymmetric hydrogen-transfer biocatalysis: application of engineered enzymes in a 2-propanol-water medium. Appl. Microbiol. Biotechnol 2012, 93, 1075–1085.
- Jakoblinnert, A.; Madenov, R.; Paul, A.; Sibilla, F.; Schwaneberg, U.; Ansorqe-Schumacher, M.B.; de Maria, P.D. Asymmetric reduction of ketones with recombinant E. coli whole cells in neat substrates. Chem. Commun 2011, 47, 12230–12232.
- Itoh, N. Quinuclidinone reductase and method for producing optically active 3-quinuclidinol. Jpn. Patent JP2010-051207, 2010.
- Itoh, N. Quinuclidinone reductase and method for producing optically active 3-quinuclidinol. Jpn. Patent JP2011-147349, 2011.
- Itoh, N.; Nakamura, M.; Inoue, K.; Makino, Y. Continuous production of chiral 1,3-butanediol using immobilized biocatalysts in a packed bed reactor: Promising biocatalysis method with an asymmetric hydrogen-transfer bioreduction. Appl. Microbiol. Biotechnol 2007, 75, 1249–1256.
- Bahulekar, R.; Ayyangar, N.R.; Ponrathnam, S. Polyethyleneimine in immobilization of biocatalysts. Enzym. Microb. Technol 1991, 13, 858–868.
|Table 1. Enzyme activity of recombinant E. coli biocatalyst.|
|Plasmid for expression||3-Quinuclidionone reduction (U/mL culture broth)||2-Propanol oxidation (U/mL culture broth)|
*The specific activity of QNR was 12.2 U/mg protein, and that of bacC was 0.9 U/mg protein.
|Table 2. Production of (R)-(−)-3-quinuclidinol by various combinations of biocatalysts.|
|Biocatalyst||Amount of cells a||Cells-mixing ratio||Production level b, molar conversion|
|(a)||pET28-QNR, pKELA||40.6 mg||4:1||100 mg/mL ± 1, 100%|
|42.3 mg||1:1||100 mg/mL ± 1, 100%|
|43.9 mg||1:4||96 mg/mL ± 2, 96%|
|42.3 mg||1:1||51 mg/mL ± 3, 34% c|
|84.5 mg||1:1||63 mg/mL ± 3, 42%c|
|(b)||pET28-bacC, pKELA||40.2 mg||4:1||98 mg/mL ± 2, 98%|
|42.0 mg||1:1||99 mg/mL ± 1, 99%|
|43.8 mg||1:4||65 mg/mL ± 3, 65%|
|42.0 mg||1:1||34 mg/mL ± 3, 22% c|
|84.0 mg||1:1||58 mg/mL ± 4, 39%c|
|(c)||pETDuet-QNR/pRSFDuet-LSADH||35.5 mg||-||100 mg/mL ± 1, 100%|
|(d)||pET28-bacC-LSADH||36.5 mg||-||98 mg/mL ± 2, 98%|
|(e)||pET28-QNR, pKELA||84.5 mg||1:1||150 mg/mL ± 2, 100% c|
|(f)||pET28-bacC, pKELA||84.0 mg||1:1||24 mg/mL ± 3, 16% b|
aTotal amount (wet weight) of recombinant E. coli cells was adjusted by harvesting from a constant culture broth (5 mL or 10 mL) with varying amounts of each of the recombinant E. coli cells;bThe average of three independent conversion experiments with standard deviation in shown;cThe final concentration of 3-quinuclidinone was 15% (w/v) and the reaction time was 48 h.
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).